SM
BLRX

Senvest Management’s BioLineRX BLRX Stock Holding History

Senvest Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,280
Closed -$543K – 72
2020
Q3 		$543K Sell
8,280
-3,000
-27% -$227K 0.03% 57
2020
Q2 		$772K Sell
11,280
-1,815
-14% -$124K 0.05% 54
2020
Q1 		$697K Sell
13,095
-2,619
-17% -$208K 0.08% 41
2019
Q4 		$1.41M Buy
15,714
+3,149
+25% +$324K 0.1% 37
2019
Q3 		$1.33M Hold
12,565
– – 0.11% 37
2019
Q2 		$2.75M Hold
12,565
– – 0.24% 29
2019
Q1 		$3.24M Buy
12,565
+4,542
+57% +$1.32M 0.24% 40
2018
Q4 		$2.1M Sell
8,023
-4,880
-38% -$2.35M 0.18% 39
2018
Q3 		$8.28M Sell
12,903
-25
-0.2% -$13.8K 0.63% 28
2018
Q2 		$6.9M Sell
12,928
-41
-0.3% -$21.8K 0.48% 38
2018
Q1 		$6.77M Hold
12,969
– – 0.52% 35
2017
Q4 		$8.48M Hold
12,969
– – 0.6% 40
2017
Q3 		$8.71M Hold
12,969
– – 0.57% 39
2017
Q2 		$6.58M Hold
12,969
– – 0.52% 39
2017
Q1 		$7.47M Buy
12,969
+5,023
+63% +$3.23M 0.54% 39
2016
Q4 		$4.39M Buy
7,946
+540
+7% +$335K 0.31% 43
2016
Q3 		$5.11M Buy
7,406
+1,500
+25% +$799K 0.37% 42
2016
Q2 		$2.83M Hold
5,906
– – 0.23% 48
2016
Q1 		$3.62M Sell
5,906
-100
-2% -$62.8K 0.3% 45
2015
Q4 		$4.68M Buy
6,006
+34
+0.6% +$28.2K 0.35% 45
2015
Q3 		$5.48M Sell
5,972
-112
-2% -$120K 0.39% 48
2015
Q2 		$9.71M Buy
6,084
+540
+10% +$669K 0.61% 44
2015
Q1 		$7.02M Buy
5,544
+1,746
+46% +$2.15M 0.43% 51
2014
Q4 		$3.69M Buy
3,798
+1,137
+43% +$988K 0.26% 55
2014
Q3 		$2.46M Buy
2,661
+9
+0.3% +$9.66K 0.23% 56
2014
Q2 		$3.31M Buy
2,652
+69
+3% +$86.4K 0.29% 51
2014
Q1 		$3.46M Buy
2,583
+1,366
+112% +$2.25M 0.27% 60
2013
Q4 		$2.05M Buy
1,217
+65
+6% +$105K 0.18% 60
2013
Q3 		$1.51M Buy
1,152
+111
+11% +$131K 0.17% 56
2013
Q2 		$1.01M Buy
+1,041
New +$1.08M 0.13% 57

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM

Senvest Management's BLRX Position: Q4 2020 in Review

Senvest Management sold out of BioLineRX (BLRX) in Q4 2020, closing a stake of 8,280 shares — an estimated $543K sold.

Senvest Management first reported a position in BLRX in Q2 2013 and held it in 30 quarters. The position peaked at $9.71M in Q2 2015. 21 funds tracked by Wall St. Rank hold BLRX as of Q4 2020.

  • Senvest Management reported no remaining BioLineRX position as of Q4 2020 after selling out during the quarter.
  • Senvest Management sold 8,280 BioLineRX shares in Q4 2020, an estimated $543K.
  • Senvest Management first reported a position in BioLineRX in Q2 2013 and held it in 30 quarters.
  • Senvest Management's BioLineRX position peaked at $9.71M in Q2 2015.
  • 21 funds tracked by Wall St. Rank held BioLineRX as of Q4 2020.

Based on Senvest Management's 13F filing for Q4 2020, filed 12 Feb 2021.